Startups
iRegene Therapeutics focuses on new generation of chemical defined cell therapy and aims to play an essential role in curing “incurable”diseases, such as degenerative diseases.
Overview
Location
China
Total raised
$40M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 1, 2026 | China's iRegene Raises USD31 Million to Advance Parkinson’s and MSA Cell Therapy Programs | (Yicai) June 1 -- Chinese cell therapy startup iRegene Therapeutics has raised CNY210 million (USD31 million) in a C1 financing round to advance clinical development of its treatments for Parkinson’s disease and multiple system atrophy (MSA... |
| Feb 23, 2026 | iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004 | CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently,... |
| Jan 19, 2026 | FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions | Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeu... |
| Oct 13, 2025 | iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data | CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead pro... |
| Sep 9, 2025 | iRegene Therapeutics Raises Series B+ Funding | iRegene Therapeutics, a Chengdu, China-based biotechnology company developing chemically induced allogeneic cell therapy, raised an undisclosed amount in Series B+ funding. The round was led by Northern Light Venture Capital, Chuangjing Cap... |
| Sep 9, 2025 | iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001 | CHENGDU, China, Sept. 9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4... |
| Sep 9, 2025 | iRegene Therapeutics: $40 Million Secured For Advancing Parkinson’s Cell Therapy | iRegene Therapeutics, a biotechnology company based in Chengdu, China, has announced the completion of its Series B+ financing round, securing over RMB 300 million (about $40 million). The round was co-led by Northern Light Venture Capital,... |
| Apr 15, 2025 | Anta's Bold Move: Reviving Jack Wolfskin in a Competitive Landscape | In a strategic play that echoes the age-old adage of "one man's trash is another man's treasure," Anta Sports has set its sights on revitalizing the beleaguered German outdoor brand Jack Wolfskin. The acquisition, valued at USD 29... |
| Apr 14, 2025 | Deals in brief: Fore Coffee’s IPO pops on debut, Accenture invests in GoUpscale, GXS Bank acquires Validus Capital, and more | Fore Coffee pops on IDX debut after massive IPO oversubscription Fore Coffee, one of Indonesia’s rising coffee chains, made a splashy entrance on the Indonesia Stock Exchange, pulling in IDR 353.44 billion (USD 21 million) through an IPO th... |
Show more
Reviews 0
FAQ about iRegene
How much funding has iRegene raised?
iRegene has raised $40M in total across 1 funding round.
What has the press written about iRegene?
Parsers VC has collected 13 articles mentioning iRegene, among them “China's iRegene Raises USD31 Million to Advance Parkinson’s and MSA Cell Therapy Programs” (Jun 1, 2026) and “iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvN...” (Feb 23, 2026).
Is iRegene still active?
Yes, iRegene is active; its latest activity on Parsers VC dates from Sep 29, 2026.